Temas de la conferencia
Over the last 12 months, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma, Corbus Pharmaceuticals, Vincerx, and Morphic are paving the way to develop a safe, efficacious integrins-targeted drug to modify disease biology, which will be a game-changer for diseases such as oncology, autoimmune, and ophthalmology, with unmet medical needs.
Organizador profesional (PCO)
Hanson Wade
Observaciones
Brochure: https://go.evvnt.com/1173725-3?pid=4832
Speakers: Bernhard Wehrle-Haller, Professor, Geneva University, Bruce Rogers, President, Morphic Therapeutics, Darren G. Woodside, Vice President of Research, Texas Heart Institute, and more.
Información e inscripción:
https://go.evvnt.com/1173725-2?pid=4832
Ms. Erin Thomas
CategoríasMedicina General
